04 · Five things to know · 01

Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 2 min read

Must read

Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients at 32 mg, its chosen dose. The Phase 1 trial has no control group, and response rate is a secondary endpoint. Single-arm, early and company-reported, so it cannot show benefit over other treatment. Erasca plans a first-line pancreatic Phase 3 in the first half of 2027.

From the edition's At a glance, as printed.

Bookmarks need a Mind Club sign-in. How sign-in works

Read it in Five things to know